ESMO Breast Cancer 2025: Potential Biomarkers Linked to Hematologic Toxicity

In this MEDtalk, Dimitrios Salgkamis, PhD student at Karolinska Institutet, presents preliminary findings from a genome-wide association study embedded in the PANTHER phase III trial, shared at ESMO Breast Cancer 2025. The analysis identified single-nucleotide polymorphisms associated with increased risk of neutropenia and leukopenia after the first chemotherapy cycle in high-risk early breast cancer patients, offering insights into potential biomarkers for treatment-related toxicity.